A multicenter, prospective cohort study of pediatric pulmonary fever Qing granules for community-acquired pneumonia in children based on a realistic medical setting

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ITMCTR

Registry ID

ITMCTR2200006542

Enrollment

Unknown

Registered

2022-08-25

Start date

2022-08-25

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

community-acquired pneumonia in children

Interventions

adding Xiaoer Feireqing granules group:None

Eligibility

Sex/Gender

All

Age

1 Years to 14 Years

Inclusion criteria

Inclusion criteria: (1) Community-acquired pneumonia in children diagnosed as a Western medicine disease; (2) TCM syndrome differentiation is heat evil pulmonary closure syndrome; (3) Age 1-14 years (=14 years); (4) Course of disease =5 days; (5) The informed consent meets the requirements. Children aged =8 years shall sign the informed consent with their guardian

Exclusion criteria

Exclusion criteria: (1) Patients with central cyanosis, severe respiratory distress, food refusal or dehydration signs, and disturbance of consciousness (lethargy, coma, convulsion); (2) Patients with nausea, vomiting, diarrhea and other gastrointestinal reactions; (3) Complicated with other respiratory infectious diseases, immune system diseases, malignant tumors; (4) Patients with liver and kidney dysfunction and severe hematopoietic system diseases; (5) Allergic to the drug in this study or the investigator considers it inappropriate to enter this study

Design outcomes

Primary

Measure	Time frame
Clinical recovery time;	—

Countries

China

Contacts

Public ContactXu Baoping

Beijing Children's Hospital

guanxiaoyu@zyyjypj.cn13370115002

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026